非黑色素瘤皮肤癌的系统治疗：最新进展。
Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances.
机构信息
Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Department of Dermatology, Vanderbilt University Medical Center, Nashville, TN, USA.
出版信息
Curr Oncol Rep. 2024 Sep;26(9):1120-1133. doi: 10.1007/s11912-024-01570-1. Epub 2024 Jul 2.
PURPOSE OF REVIEW
This review provides an update on approved and emerging systemic therapies in the treatment of locally advanced or metastatic non-melanoma skin cancers (squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma).
RECENT FINDINGS
Many studies demonstrate the effectiveness of immunotherapy for all types of non-melanoma skin cancer. For basal cell carcinoma (BCC), hedgehog inhibitors (HHI) remain first-line but with poor tolerability. Numerous clinical trials studying both neoadjuvant and adjuvant use of anti-PD-1 and anti-PD-L1 therapies in advanced NMSC are under investigation. There is a growing number of systemic therapies available to treat non-melanoma skin cancers. The advent of immunotherapy has revolutionized the field and greatly improved survival compared to historical survival rates with cytotoxic chemotherapy.
目的综述
本文就局部晚期或转移性非黑色素瘤皮肤癌（鳞状细胞癌、基底细胞癌、默克尔细胞癌）的治疗中已获批和新出现的系统疗法进行更新。
最新发现
许多研究表明免疫疗法对所有类型的非黑色素瘤皮肤癌均有效。对于基底细胞癌（BCC），Hedgehog 抑制剂（HHI）仍为一线治疗药物，但耐受性差。目前正在开展多项临床试验，以研究抗 PD-1 和抗 PD-L1 治疗药物在晚期 NMSC 中的新辅助和辅助应用。目前有越来越多的系统疗法可用于治疗非黑色素瘤皮肤癌。与细胞毒性化疗的历史生存率相比，免疫疗法的出现彻底改变了这一领域，并显著提高了生存率。
Zotero 插件